Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma

A. Chiappa*, A. P. Zbar†, R. A. Audisio‡, B. E. Leone¶, F. Biella* and C. Staudacher¶

*Department of General Surgery, University of Milan, European Institute of Oncology, Milan, Italy, †St James's University Hospital, Leeds, UK, ‡Division of General Surgery, Whiston Hospital, Prescot, UK, and ¶Department of Emergency Surgery and Department of Pathology, University of Milan, San Raffaele Scientific Institute, Milan, Italy

Aims: Prognostic analysis of hepatocellular carcinoma (HCC) in the cirrhotic patient undergoing hepatic resection is necessary in order to determine the clinical effect of hepatectomy on prognosis.

Patients and methods: Univariate and multivariate retrospective analyses were performed in 51 cirrhotic patients (38 men, 13 women; mean age 65 years, range 43–81 years) with supervening HCC undergoing hepatic resection between January 1993 and December 1997.

Results: Segmental liver resection was performed in 39 patients (76%) with non-anatomical (wedge) resections in the remainder of cases. The post-operative mortality rate was 8%. The tumours recurred in 23 patients (45%), with 12 patients (52% of recurrences) recurring within 1 year of surgery and 22 patients (96% of recurrences) within 3 years. Recurrent disease was most frequently intrahepatic (22 patients). Significant risk factors for recurrence were micro/ macro vascular invasion, and symptoms.

Conclusions: The recurrence rate of hepatocellular carcinoma in patients with cirrhosis undergoing surgical resection alone is high and actuarial survival at 4 years is low. Other approaches to the treatment of hepatocellular carcinoma in patients with cirrhosis require consideration.

Key words: cirrhosis; hepatocellular carcinoma; hepatic resections; survival; disease-free survival; prognostic factors.

Introduction

The prevalence of cirrhosis in hepatocellular carcinoma (HCC) patients ranges from 60 to 90%.1 Frequent monitoring with ultrasonography (US) and α-fetoprotein (AFP) levels have made it possible to discover small tumours (< 2 cm in maximal diameter) in patients with cirrhosis and chronic viral hepatitis.2 Surgical resection with partial hepatic resection or liver transplantation are the only potentially curative treatments.3–6 However, hepatic resection can only be offered to patients with good liver function and well-defined, solitary tumours treatable with limited hepatic resection. Liver transplantation is the only option in patients with poor liver function or in non- resectable tumour(s), provided extrahepatic malignancy has been excluded.

The present study details experience in our institution gained in the surgical resection of HCC in patients with cirrhosis.

Patients and methods

Fifty-one cirrhotic patients (38 men, 13 women; mean age 65 years, range 43–81 years) underwent hepatic resection for supervening HCC in the Department of Emergency Surgery at the University of Milan between January 1993 and December 1997. Their clinical features and demographic characteristics are summarized in Table 1.

Thirty-eight patients (74%) were asymptomatic, with HCC being discovered by US during routine follow-up for cirrhosis. The remainder of cases (26%) were symptomatic. Abdominal pain and upper gastrointestinal haemorrhage were the most frequently presenting symptoms. Nineteen patients (37%) had hepatitis C virus, 11 (21%) hepatitis C plus hepatitis B virus, 10 (20%) isolated hepatitis B virus, eight (16%) alcoholic cirrhosis and three (6%) cryptocogenic cirrhosis. Each case was classified according to the Child–Pugh criteria for hepatic functional reserve. All patients were also evaluated with indocyanine green retention at 15 min as predictor of liver reserve. Thirty-eight patients (74%) were in Child's group A, 12 (24%) in Child's group B, and one (2%) in Child's group C.

US before operation detected a single nodule in 31 patients (61%), with a mean size of 5 ± 4 cm in maximal diameter.
Table 1. Clinical and surgical features for the 51 cirrhotic patients with supervening HCC undergoing resection

<table>
<thead>
<tr>
<th>Feature</th>
<th>Value (n)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age (years)</td>
<td>65 (8)</td>
<td>(range 43–81)</td>
</tr>
<tr>
<td>Sex (m:f)</td>
<td>38:13</td>
<td>2.9:1 (ratio)</td>
</tr>
<tr>
<td>Aetiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-necrotic HCV</td>
<td>19 (37)</td>
<td></td>
</tr>
<tr>
<td>Post-necrotic HBV and HCV</td>
<td>11 (21)</td>
<td></td>
</tr>
<tr>
<td>Post-necrotic HBV</td>
<td>10 (20)</td>
<td></td>
</tr>
<tr>
<td>Alcoholic</td>
<td>8 (16)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>3 (6)</td>
<td></td>
</tr>
<tr>
<td>Child–Pugh classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>38 (74)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>12 (24)</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>HCC symptomatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>13 (26)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>38 (74)</td>
<td></td>
</tr>
<tr>
<td>AFP (ng/ml)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20 ng/ml</td>
<td>19 (37)</td>
<td></td>
</tr>
<tr>
<td>≥20 ng/ml</td>
<td>32 (63)</td>
<td></td>
</tr>
<tr>
<td>Types of hepatic resection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Segmentectomies</td>
<td>19 (37)</td>
<td></td>
</tr>
<tr>
<td>Bisegmentectomies</td>
<td>11 (22)</td>
<td></td>
</tr>
<tr>
<td>Non-segmental resections</td>
<td>12 (23)</td>
<td></td>
</tr>
<tr>
<td>Major hepatectomies</td>
<td>9 (18)</td>
<td></td>
</tr>
</tbody>
</table>

Values in parentheses are percentages. SD, standard deviation; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein (normal value: 0–12 ng/ml).

and two nodules of HCC in seven patients (14%) with a mean size of 6±3 cm. Abdominal computed tomography (CT) with intravenous contrast was performed in 45 patients (88%) and showed one main tumour in 35 cases (78%), two separate nodules in nine (20%), and three nodules in one case (2%). Satellite lesions, defined as a minute contrast enhancement near the primary lesion, were occasionally detected in 12 subjects (26%).

Segmental resection was performed in 39 patients (76%), while the remaining 12 patients (24%) underwent non-anatomical (wedge) resection. Three patients (6%) had repeat hepatic resections because of tumour recurrence in the hepatic remnant. Intra-operative ultrasonography (IOUS) was used in 31 patients (61%). At operation the tumour could not be located by inspection or palpation in 12 patients (24%) but was found by IOUS. This examination detected additional nodules in one patient who had been diagnosed as having a solitary tumour before surgery. Cirrhosis was histologically confirmed in all patients. Patients were staged according to the UICC TNM classification for HCC.9

Tumour differentiation was recorded according to the standard grading of Edmonson and Steiner.10 Thirty-nine patients had a clear surgical margins of more than 1 cm, and 12 patients had a clear surgical margin of less than 1 cm. There were no patients with hepatic resection margin involved.

All patients with HCC complicating their cirrhosis were resected for cure. The mean tumour size was 6±4 cm in maximal diameter (Table 2). According to the UICC TNM staging, seven patients (14%) were stage 1, 18 (35%) stage 2, 18 (35%) stage 3A, and eight (16%) stage 4A.

Follow-up

All cases were followed at 4-month intervals with serial AFP levels, US and CT scanning. Recurrence of HCC in relation to clinical and pathological characteristics of the tumour and type of cirrhosis was evaluated. The parameters used in the univariate analysis were as follows: sex, age, cirrhosis aetiology, presence or absence of alcoholism, hepatitis C virus, hepatitis B surface antigen, symptoms, AFP level, type of resection and hepatic resection margin (more or less than 1 cm), tumour size and number, type of tumour, satellite nodules, tumour differentiation, tumour capsule, capsule invasion, vascular invasion, and presence of associated dysplasia.

Analysis of the data

Overall and disease-free survival analyses were conducted using the Kaplan–Meier method,11 with comparisons between groups performed by the log-rank test.12 Disease-free survival was estimated from the date of the hepatic resection to the date of diagnosis of recurrent disease using US, CT scan, hepatic angiography or biopsy. Multivariate analysis using Cox’s logistic regression technique13 was employed for variables found to be significant on univariate analysis. Statistical significance is recorded for P-values <0.05.

Results

There were four peri-operative deaths (8%). Three patients died from hepatic failure and one from post-operative myocardial infarction. Post-operative ascites occurred in seven patients with progressive hepatorenal syndrome in one case. Major peri-operative complications occurred in 20% of cases including severe gastrointestinal bleeding in one, cardiopulmonary complications in three, significant but reversible hepatic failure in five, and abdominal wound dehiscence in one.

The mean hospital stay was 13 days (range 6–36 days).
Resection of hepatocellular carcinoma in cirrhotics

The mean follow-up was 28 months (range 4–60 months).

The 1-year, 3-year and 4-year overall and disease-free survival rates were 89, 53 and 53%, respectively, and 66, 34 and 30%, respectively (Fig. 1).

Recurrent HCC was diagnosed in 23 patients (45%) with 12 patients (52% of recurrences) recurring within 1 year of surgery and 22 patients (96% of recurrences) within 3 years. Recurrent disease was most frequently detected in the liver parenchyma, usually as a solitary tumour near the resection margin.

Extrahepatic recurrences were detected in four cases (17%), all presenting with solitary lung metastases (Table 3).

Tumour size did not affect either overall survival or disease-free survival. The 4-year overall survival rates for tumours <2 cm, 2–5 cm and >5 cm in maximal diameter were 50, 60 and 40%, respectively. The 4-year disease-free survival rates for tumours <2 cm, 2–5 cm and >5 cm in maximal diameter were 17, 36 and 27%, respectively.

Histologic vascular invasion was found to be a relevant prognostic factor for overall and disease-free survival. The 1-year, 3-year and 4-year overall survival rates for patients with vascular invasion were 67, 15 and 15%, respectively, and 100, 73 and 73%, respectively, in those cases without vascular invasion (P<0.0001) (Fig. 2).

Fig. 2. Overall survival for the 51 cirrhotic patients with supervening hepatocellular carcinoma undergoing resection: the effect of microvascular invasion. (No vascular invasion [——] vs vascular invasion [– – –]; P<0.0001.)

The 1-year, 3-year and 4-year disease-free survival rates for patients with vascular invasion were 40, 13 and 13%, respectively, and 79, 46 and 38%, respectively, in those cases without vascular invasion (P<0.005).

Four patients with microscopic vascular invasion developed recurrence within 1 year following surgery and three-quarters of those with microvascular invasion (12 patients) died within 3 years of hepatectomy.

Fig. 3. Overall survival for the 51 cirrhotic patients with supervening hepatocellular carcinoma undergoing resection. (Solitary [——] vs multiple [– – –] tumours: P<0.01.)

The 1-year, 3-year and 4-year disease-free survival rates for patients with vascular invasion were 40, 13 and 13%, respectively, and 79, 46 and 38%, respectively, in those cases without vascular invasion (P<0.005).

Four patients with microscopic vascular invasion developed recurrence within 1 year following surgery and three-quarters of those with microvascular invasion (12 patients) died within 3 years of hepatectomy.

The 1-year, 3-year and 4-year overall survival rates for patients with a solitary tumour were 92, 66 and 66%, respectively, whereas equivalent survival rates for patients with more than one tumour were 78, 11 and 11%, respectively (P<0.01) (Fig. 3).

The 1-year, 3-year and 4-year disease-free survival rates for patients with a solitary tumour were 71, 41 and 35%,
Discussion and conclusions

Strict follow-up of patients with cirrhosis, mainly by US examination, has increased the frequency of diagnosis of small resectable HCC.2,4 This is reflected in this series by the fact that 74% of patients were asymptomatic and detected on routine follow-up US. Hepatocectomy appears to be relatively safe even in cirrhotic patients with supervening HCC with an overall mortality of 8% in our series. Moreover, the 5-year survival in such patients is between 33 and 46% in most Western countries1,14,15 and 25 and 33% in reported Asian series.16-18

Intra-operative ultrasonography is a valuable tool not only for detecting the tumour, but also for establishing adequate resection margins sparing as much parenchyma as possible.19-22 In this study, 24% of tumours were not found on careful inspection or palpation of the cirrhotic liver but were only located with IOUS examination.

The introduction of limited hepatectomy using IOUS23,24 has an acceptable morbidity in cirrhosis complicated by supervening HCC.25-27 There has been considerable improvement in the prediction of the safety of liver resection in selected patients with cirrhosis and impaired hepatic reserve.28,29 however, tumour recurrence during follow-up in this group is common.30,31 The recurrence rate in this series was 49% in patients surviving surgery, and was similar to that of other series.32-34 The cumulative recurrence rate at 3 years was 57% in our study and was similar to that reported by Belghiti et al.,31 who found an overall intrahepatic recurrence of 60%, with a cumulative intrahepatic recurrence rate of 81% at 3 years depending on the size of the original primary, the presence of a tumour capsule and the pre-operative AFP level.

The majority of tumour recurrences in our study were intrahepatic and occurred within the first year after resection, as reported by other authors.18,34 Most presented as solitary nodules close to the original resection line. This has been a similar finding in other studies concerning cirrhotics with supervening HCC35,36 as well as in HCC patients without cirrhosis,37 where intrahepatic recurrence most commonly follows small non-anatomical resections.

The most significant prognostic factors reported for recurrence have included: more than one primary tumour, tumour size greater than 2 cm in maximal diameter, the presence of a tumour capsule, and vascular invasion.3,30,38-42 In the present series of cirrhotic subjects, tumour size was not a significant prognostic factor and the presence of tumour encapsulation did not reach significance. Vascular invasion and symptomatic tumours were significant prognostic factors in multivariate analysis, which correlated with recurrence. This highlights the importance of close follow-up in patients with cirrhosis in order to detect asymptomatic tumours.

If tumour recurrence occurs, there are several treatment options43 depending on several parameters such as size and location of the tumour, number of tumour nodules and functional hepatic reserve. One option is to repeat the hepatic resection and survival in these cases has been as high as 75% at 3 years.44 Ringe et al.45 have found a high incidence of HCC recurrence with re-resection, and they have proposed liver transplantation in cases of resectable
tumour recurrence; achieving better results with this technique. Tumour recurrences may also be treated by chemoembolization,1,3,14 or intra-tumoural alcohol injection.41 When no treatment is possible, the mean survival is only as long as 2 months.3

Hepatic transplantation is considered the best therapeutic option for patients with small hepatocellular carcinoma complicating liver cirrhosis, though the limited organ availability, and its high costs conflict with the popularization of this procedure.3,40,45

The poor results obtained with resection of HCC in cirrhotics in terms of tumour recurrence and patient survival invite reconsideration of the best treatment options for the cirrhotic patient with supervening HCC and good functional reserve.

References

10. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a clinical application of cytochrome a (cytochrome oxidase) and 2,3-DPNH diaphorase in normal and neoplastic liver. Cancer 1954; 7: 462–503.
37. Bismuth H, Chiche L, Castaing D. Surgical treatment of


Accepted for publication 30 September 1999